Evidence map›Paper›PMID 32617767›Full record

ArticleDigestive diseases and sciences2021

Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease.

Waseem Amjad, Joseph Alukal, Talan Zhang, Anurag Maheshwari, Paul J Thuluvath

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04588077 (Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04588077 phase4recruitingnot on this map

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

TypeinterventionalSponsorMercy Medical CenterRan2020 to 2028Enrolled200ConditionsHepatitis B, Cirrhosis, Liver, Chronic Liver DiseaseArmsHeplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. [Hepatitis B vaccines-history, achievements, challenges, and perspectives].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Vaccination in Chronic Liver Disease: An Update.Journal of clinical and experimental hepatology
    Review
  18. Article
  19. Vaccine Adjuvants in the Immunocompromised Host: Science, Safety, and Efficacy.Transplant infectious disease : an official journal of the Transplantation Society
    Review
  20. Vaccination Strategies for a Liver Transplant Recipient.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Waseem AmjadInstitute of Digestive Heath and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA.
Joseph AlukalInstitute of Digestive Heath and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA.
Talan ZhangInstitute of Digestive Heath and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA.
Anurag MaheshwariInstitute of Digestive Heath and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA.
Paul J ThuluvathInstitute of Digestive Heath and Liver Diseases, Mercy Medical Center, Baltimore, MD, 21202, USA. thuluvath@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of the two-dose hepatitis B virus (HBV) vaccine (Heplisav-B

aimsTo compare the immunogenicity achieved with Heplisav-B and the conventional three-dose vaccine (Engerix-B

methodsWe retrospectively identified all adults who completed Heplisav-B or Engerix-B regimens from August 1, 2015, to January 31, 2019. Post-vaccination immunity was assessed by quantitative HBV surface antibody (HBsAb) measurement.

resultsWe identified 166 patients (106 Engerix-B and 60 Heplisav-B) with chronic liver disease (mean age 59.0 ± 11.3 years, 52% male, 34% cirrhosis, mean MELD score of those with cirrhosis 10.1 ± 5.4) who had completed the vaccinations and had data available on post-vaccination HBsAb levels at least 2 months after completion of the vaccine regimen. Seroprotective HBsAb levels (> 10 mIU/ml) were achieved in 63% with Heplisav-B and in 45% with Engerix-B (p = 0.03). Univariable analysis showed that age (p = 0.01), insurance (p = 0.02), renal failure (p = 0.02), COPD (p = 0.05), and cirrhosis (p < 0.01) had a significant effect on achieving immunogenicity. On multivariable analysis, patients with cirrhosis (adjusted odds ratio [aOR]: 0.27, 95% CI 0.13-0.55), COPD (aOR: 0.06, 95% CI 0.01-0.56), or renal failure (aOR 0.36, 95% CI 0.14-0.93) had a lower likelihood of achieving immunity, and patients who received Heplisav-B

conclusionThe two-dose recombinant hepatitis B vaccine resulted in better seroconversion than the three-dose vaccine. Cirrhosis, COPD, and renal failure were associated with a lower likelihood of achieving immunogenicity.

Indexed as

AgedDose-Response Relationship, DrugDrug Administration ScheduleEnd Stage Liver DiseaseFemaleFollow-Up StudiesHepatitis B VaccinesHumansMaleMiddle AgedRetrospective StudiesSeroconversionVaccinationVaccines, SyntheticEngerix-BHepatitis B VaccinesVaccines, SyntheticCirrhosisImmunityPredictors of HBV vaccine responseTwo-dose versus three-dose hepatitis B vaccine

Identifiers

PMID32617767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.